Literature DB >> 16972172

Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A/B and C.

Markus Ries1, Ellen Schaefer, Till Lührs, Latha Mani, Jana Kuhn, Marie T Vanier, Frank Krummenauer, Andreas Gal, Michael Beck, Eugen Mengel.   

Abstract

Laboratory diagnosis of lysosomal storage disorders, especially sphingomyelinase deficiency (Niemann-Pick disease type A/B) and Niemann-Pick disease type C (NPC) can be challenging. We therefore aimed to analyse the feasibility of first-step screening with specific chitotriosidase cut-off values in children </= 10 years of age with visceral organomegaly (hepatomegaly, splenomegaly, or hepatosplenomegaly) in whom a storage disorder was suspected. We conducted a retrospective, cross-sectional, referral, single-centre study to assess diagnostic test properties in 106 individuals. Median chitotriosidase activity was 12 655 nmol/h per ml (interquartile range 4693-20982) in Gaucher disease (GD); 780 (465-1298) in SMD (sphingomyelinase deficiency); 925 (319-1215) in NPC and 50 (29-54) in patients with miscellaneous diseases. To restrict the differential diagnosis to GD, SMD or NPC, chitotriosidase activity above 200 nmol/h per ml had a sensitivity of 96%, specificity of 100%, positive predictive value (PPV) of 100%, and negative predictive value (NPV) of 95%. For GD alone, chitotriosidase activity above 4000 nmol/h per ml had a sensitivity of 77%, specificity of 100%, PPV of 100% and NPV of 92%. Of the 44 patients analysed, 4.5% were homozygous and 36.4% heterozygous for chitotriosidase gene duplication. Adjusting for the chitotriosidase genotype, chitotriosidase activities were higher in GD type III than in GD type I. We conclude that, in the above setting, the degree of elevation of chitotriosidase activity can be applied to increase the likelihood of GD, SMD, or NPC and guide the choice of the appropriate confirmatory assay.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972172     DOI: 10.1007/s10545-006-0363-3

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  25 in total

1.  Type C Niemann-Pick disease: spectrum of phenotypic variation in disruption of intracellular LDL-derived cholesterol processing.

Authors:  M T Vanier; C Rodriguez-Lafrasse; R Rousson; N Gazzah; M C Juge; P G Pentchev; A Revol; P Louisot
Journal:  Biochim Biophys Acta       Date:  1991-06-05

2.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

Authors:  T Cox; R Lachmann; C Hollak; J Aerts; S van Weely; M Hrebícek; F Platt; T Butters; R Dwek; C Moyses; I Gow; D Elstein; A Zimran
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

3.  Allelic frequency determination of the 24-bp chitotriosidase duplication in the Portuguese population by real-time PCR.

Authors:  M R Rodrigues; M C Sá Miranda; O Amaral
Journal:  Blood Cells Mol Dis       Date:  2004 Nov-Dec       Impact factor: 3.039

4.  Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages.

Authors:  R G Boot; T A van Achterberg; B E van Aken; G H Renkema; M J Jacobs; J M Aerts; C J de Vries
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

5.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

6.  Niemann-Pick disease type A and B are clinically but also enzymatically heterogeneous: pitfall in the laboratory diagnosis of sphingomyelinase deficiency associated with the mutation Q292 K.

Authors:  K Harzer; A Rolfs; P Bauer; M Zschiesche; E Mengel; J Backes; B Kustermann-Kuhn; G Bruchelt; O P van Diggelen; H Mayrhofer; I Krägeloh-Mann
Journal:  Neuropediatrics       Date:  2003-12       Impact factor: 1.947

7.  Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages.

Authors:  R G Boot; G H Renkema; A Strijland; A J van Zonneveld; J M Aerts
Journal:  J Biol Chem       Date:  1995-11-03       Impact factor: 5.157

8.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

9.  [Plasma chitotriosidase activity in Argentinian patients with Gaucher disease, various lysosomal diseases and other inherited metabolic disorders].

Authors:  R Dodelson de Kremer; A Paschini de Capra; C J Angaroni; A Giner de Ayala
Journal:  Medicina (B Aires)       Date:  1997       Impact factor: 0.653

10.  A 24-bp duplication in exon 10 of human chitotriosidase gene from the sub-Saharan to the Mediterranean area: role of parasitic diseases and environmental conditions.

Authors:  L Malaguarnera; J Simporè; D A Prodi; A Angius; A Sassu; I Persico; R Barone; S Musumeci
Journal:  Genes Immun       Date:  2003-12       Impact factor: 2.676

View more
  30 in total

1.  [International Children's Day].

Authors: 
Journal:  Pediatriia       Date:  1977-06

Review 2.  Laboratory diagnostic approaches in metabolic disorders.

Authors:  Ruben Bonilla Guerrero; Denise Salazar; Pranoot Tanpaiboon
Journal:  Ann Transl Med       Date:  2018-12

3.  Biochemical and Molecular Chitotriosidase Profiles in Patients with Gaucher Disease Type 1 in Minas Gerais, Brazil: New Mutation in CHIT1 Gene.

Authors:  Talita E R Adelino; Gustavo G Martins; Aretta A A Gomes; Adriana A Torres; Daniel A S Silva; Vinícius D O Xavier; João Paulo O Guimarães; Sérgio S S Araújo; Rachel A F Fernandes; Maria Christina L A Oliveira; Ana Lúcia B Godard; Eugênia R Valadares
Journal:  JIMD Rep       Date:  2012-10-13

4.  Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis.

Authors:  Koenraad R P Veys; Mohamed A Elmonem; Maria Van Dyck; Mirian C Janssen; Elisabeth A M Cornelissen; Katharina Hohenfellner; Giusi Prencipe; Lambertus P van den Heuvel; Elena Levtchenko
Journal:  J Am Soc Nephrol       Date:  2020-04-09       Impact factor: 10.121

Review 5.  Cataplexy and sleep disorders in Niemann-Pick type C disease.

Authors:  Sona Nevsimalova; Vera Malinova
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

6.  New variants in Spanish Niemann-Pick type c disease patients.

Authors:  Laura López de Frutos; Jorge J Cebolla; Luis Aldámiz-Echevarría; Ángela de la Vega; Sinziana Stanescu; Carlos Lahoz; Pilar Irún; Pilar Giraldo
Journal:  Mol Biol Rep       Date:  2020-02-14       Impact factor: 2.316

Review 7.  Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders.

Authors:  Monique Piraud; Magali Pettazzoni; Pamela Lavoie; Séverine Ruet; Cécile Pagan; David Cheillan; Philippe Latour; Christine Vianey-Saban; Christiane Auray-Blais; Roseline Froissart
Journal:  J Inherit Metab Dis       Date:  2018-03-19       Impact factor: 4.982

8.  Human chitinases and chitinase-like proteins as indicators for inflammation and cancer.

Authors:  Julia Kzhyshkowska; Alexei Gratchev; Sergij Goerdt
Journal:  Biomark Insights       Date:  2007-05-03

Review 9.  Niemann-Pick disease type C.

Authors:  Marie T Vanier
Journal:  Orphanet J Rare Dis       Date:  2010-06-03       Impact factor: 4.123

Review 10.  Diagnostic workup and management of patients with suspected Niemann-Pick type C disease.

Authors:  Apostolos Papandreou; Paul Gissen
Journal:  Ther Adv Neurol Disord       Date:  2016-03-02       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.